Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 5/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992903 | 0.92 | FABP3 (0.52) | FABP3FABP4FABP5DHODHPDE10A | |
| SCHEMBL15782876 | 0.81 | KDM4E (0.49) | FABP3FABP4FABP5DHODHPDE10A | |
| SCHEMBL10432877 | 0.78 | DHODH (0.51) | DHODHPDE10ACYP2D6CYP2C19TSHR | |
| SCHEMBL28983359 | 0.78 | DHODH (0.51) | FABP3FABP4FABP5DHODHPDE10A | |
| SCHEMBL11075264 | 0.77 | KDM4E (0.61) | KDM4EALDH1A1HPGDLMNAGAA | |
| SCHEMBL18285397 | 0.77 | FABP3 (0.44) | FABP3FABP4FABP5DHODHCYP2C19 | |
| SCHEMBL2566789 | 0.77 | BID (0.46) | DHODHPDE10ATSHRKDM4EALDH1A1 | |
| SCHEMBL14952438 | 0.76 | BID (0.48) | DHODHPDE10ATSHRKDM4EALDH1A1 | |
| SCHEMBL621336 | 0.76 | HSD17B10 (0.56) | FABP3FABP4FABP5PDE10ACYP2D6 | |
| SCHEMBL6293298 | 0.76 | FABP3 (0.61) | FABP3FABP4FABP5DHODHPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-20080207673-A1 | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins | XILINAS MICHEL | 2008-08-28 | — | — | US | claimed |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | UCL BUSINESS PLC (GB) | 2018-10-02 | — | — | US | disclosed |
| EP-3145914-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL Business PLC (GB) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2006117660-A2 | METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS | CLIO PHARMACEUTICAL CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | FABP3 45/4885FABP4 929/4885FABP5 1039/4885 |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | AGTR1, CBR3, CBR1 | FABP3 47/4885FABP4 989/4885FABP5 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.